Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

Number of ongoing Clinical Trials (for drugs) involving Prostate Cancer by Phase

  • There are currently 988 ongoing clinical trials involving Prostate Cancer

  • Of the 988 trials,405 trials are in Phase II

  • Furthermore, 406 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Prostate Cancer by Phase

Published: October 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Prostate Cancer, an oncology condition. The largest number of ongoing clinical trials for Prostate Cancer is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Prostate Cancer-related drug trials.

National Cancer Institute US: The leading ongoing Prostate Cancer related clinical trial sponsor 

National Cancer Institute US is the top sponsor for Prostate Cancer-related ongoing clinical trials. 

University of Texas MD Anderson Cancer CenterJohnson & Johnson, Memorial Sloan Kettering Cancer Center, and Sidney Kimmel Comprehensive Cancer Center are among other notable clinical trial sponsors involved in Prostate Cancer. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Prostate Cancer

Enzalutamide (Xtandi), Abiraterone acetate (Zytiga), and Olaparib (Lynparza) are among the key marketed drugs involving Prostate Cancer.

Enzalutamide (Xtandi) is a phenylimidazolidine derivative, acts as anti-neoplastic agent. It functions via Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR) Antagonist mechanism of action. It is formulated as soft gelatin capsules and tablets for oral route of administration. Enzalutamide is marketed for the treatment of Prostate Cancer and several other indications including Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, and Metastatic Prostate Cancer. Enzalutamide was first approved in 2012 and is marketed globally including the US, France, Germany, China, and Japan by several pharma giants including Astellas Pharma Inc, and PT Meprofarm. 

Abiraterone acetate (Zytiga) is an antineoplastic agent. It functions via Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) Inhibitor mechanism of action. It is formulated as tablets and film coated tablets for oral route of administration. Zytiga is indicated in combination with prednisone for the treatment of metastatic prostate cancer (castration-resistant prostate cancer) in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in patients who have received prior chemotherapy containing docetaxel after failure of androgen deprivation therapy and in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer. Abiraterone acetate was first approved in 2011 and is marketed globally including the US, France, Germany, China, and Japan by Johnson & Johnson



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward